glp-1 weight loss clinical trials New oral drug delivers up to 12% in 36 weeks 3 Takeaways from the Landmark

PlexusDx sources all medications exclusively from licensed 503A compounding pharmacies to ensure consistent quality and safety

Retatrutide helped people with obesity drop about one-quarter of their starting weight, on average, during 48 weeks taking the drug, according to Phase 2 trial results published online Monday in the New England Journal of Medicine

It is unclear at this point if this suspension of the dividend is permanent, but the market is likely thinking it is and has sent the stock down another 20% year to date

The GLP-1 revolution: Novo Nordisk & Lilly now lead with semaglutide (Wegovy) & tirzepatide (Zepbound), showing double-digit weight loss percentages with fewer risks

What These Findings Mean for GLP-1 Drug Users The study demonstrates how artificial intelligence can help researchers better understand patient experiences with GLP-1 drugs

Check for air bubbles, which can reduce the actual volume of liquid in the syringe